Results 61 to 70 of about 4,992,809 (126)

The Role of “Adult‐Onset” Cancer Predisposition Genes in Pediatric Cancer: A Comprehensive Review

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Current literature estimates that 10% of pediatric cancers are caused by pathogenic or likely pathogenic (P/LP) germline variants in cancer predisposition genes (CPGs). Variants in CPGs thought to increase cancer risk exclusively during adulthood are referred to as “adult‐onset” CPGs (aoCPGs).
Maria Rozo, Miriam A. Bornhorst, Angela J. Waanders, Sara Zarnegar‐Lumley, Ashwin Lakshman Koppayi, Lucy A. Godley   +5 more
wiley   +1 more source

Characterization of CD123 expression by mast cells in systemic mastocytosis with multicolor flow cytometry

Cytometry Part B: Clinical Cytometry, Volume 110, Issue 5, Page 326-334, September 2026.
Abstract Systemic mastocytosis (SM) is a clonal mast cell (MC) disorder characterized by aberrant immunophenotypes, including expression of CD25, CD2, and occasionally CD30. CD123, the α‐subunit of the interleukin‐3 receptor, is a therapeutic target in hematologic malignancies and has been reported to be expressed on neoplastic MCs by ...
Ryan C. Shean, Tracy I. George, David P. Ng   +2 more
wiley   +1 more source

Two Blastic Plasmacytoid Dendritic Cell Neoplasms treated with the CD123‐targeted agent Tagraxofusp presenting divergent outcomes

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Sven C. Engler, Elisabeth M. Walde, Edgar Jost, Amir S. Yazdi, David Kluwig   +4 more
wiley   +1 more source

High‐dimensional spectral flow cytometry uncovers progressive T‐cell exhaustion and myeloid cell reprogramming in a CLL mouse model

HemaSphere, Volume 10, Issue 9, September 2026.
Abstract Chronic lymphocytic leukemia (CLL) exhibits marked clinical heterogeneity that cannot be fully explained by genetic alterations, underscoring the critical role of the tumor microenvironment in disease progression and therapeutic resistance.
Hannah Briesch, Mariana Coelho, Alessia Floerchinger, Yuliia Borysovych, Nicolas Aubert, Daniel Medina‐Gil, Manina Breitinger, Marc Zapatka, Stella E. Autenrieth, Martina Seiffert   +9 more
wiley   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm: Report of a Case [PDF]

, 2012
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), also known as CD4+/CD56+ hematodermic neoplasm, is a rare, highly aggressive hematopoietic malignancy characterized by cutaneous, lymph node and bone marrow involvement, high risk of a leukemic ...
MASCOLO, MASSIMO, Lucia Gallo, SCALVENZI, MASSIMILIANO, Franco Palmisano, DE ROSA, GAETANO, Orlando Zagaria   +5 more
core  

Blastic plasmacytoid dendritic cell neoplasm: an early presentation [PDF]

, 2019
A blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a cutaneous lymphoma derived from a plasmacytoid dendritic precursor cell that exhibits aggressive clinical behavior. Herein, we report a 46-year-old woman with a complaint of a painless nodule on
Dias Júnior, Leônidas Braga, Palheta, Caroline da Silva Alves, Brito, Caio Vinicius Botelho, Fernandes, Cassia Michelle Almeida, Einecke, Yandra Sherring, Carneiro, Francisca Regina Oliveira, Silveira, Samira Oliveira, Pinto, Érica Baptista   +7 more
core   +1 more source

Tumor Plasticity and Microenvironmental Crosstalk as Drivers of Metastasis and Therapy Resistance

MedComm, Volume 7, Issue 8, August 2026.
The graphical abstract is a schematic illustration of the bidirectional crosstalk between tumor plasticity and the tumor microenvironment (TME) in driving metastasis and therapy resistance. Tumor‐intrinsic factors such as genetic mutations and epigenetic reprogramming enable dynamic transitions between epithelial, mesenchymal, and cancer stem cell ...
Gunjan Dagar, Manisha Dagar, Ashna Gupta, Anju Surendranath, Suraja Kumar Das, Mohd Umar Rehmani, Mukesh Tanwar, Sameer Mirza, Muzafar A. Macha, Ammira S. Al‐Shabeeb Akil, Shahab Uddin, Mayank Singh, Ajaz A. Bhat   +12 more
wiley   +1 more source

CD103 Expression on Blastic Plasmacytoid Dendritic Cell Neoplasms in Peripheral Blood and Bone Marrow Samples

, 2020
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive neoplasm which is typically CD4+, CD56+, and CD123+. There is limited information regarding CD103 expression on blastic plasmacytoid dendritic cell neoplasms.
Thomason Ron, Ullery Sally, Ron Lee, Sally Ullery, Ron Thomason, Lee Ron   +5 more
core   +1 more source

Genetic analysis of primary lung interdigitating dendritic cell sarcomas

The Journal of Pathology, Volume 269, Issue 4-5, Page 387-398, August 2026.
Abstract Interdigitating dendritic cell sarcomas (IDCSs) are rare tumors that commonly arise in the hematopoietic system and rarely outside. The genetic drivers of IDCS carcinogenesis are unknown; therefore, therapeutic options are limited. We investigated somatic gene mutations and copy‐number alterations (CNAs) in nine IDCSs arising in the lung by ...
Mikhail S Ermakov, Juliana Faria Filipe, Sylvia Eidenhammer, German Ott, Iris Halbwedl, Karl Kashofer, Helmut Popper   +6 more
wiley   +1 more source

Plasma Elastase Screening in Hematological Disease Reveals Its Potential as a Diagnostic and Prognostic Biomarker in Hematological Malignancies

International Journal of Laboratory Hematology, Volume 48, Issue 4, Page 795-806, August 2026.
ABSTRACT Introduction Neutrophil‐extracellular traps are net‐like material released by triggered neutrophils and composed of decondensed chromatin linked to nuclear proteins. Elastase, one of the fourth most represented neutrophil‐specific serine proteases stored in azurophil granules of naïve neutrophils, exerts various actions, including degradation ...
Pasqualina Scala, Anna Maria Della Corte, Angela Bertolini, Marisa Gorrese, Francesca Picone, Bianca Serio, Danilo De Novellis, Laura Mettivier, Luca Pezzullo, Maria Carmen Martorelli, Denise Morini, Matteo D'Addona, Bianca Cuffa, Carmine Selleri, Valentina Giudice   +14 more
wiley   +1 more source